Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

CGEN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Compugen Ltd.NASDAQ: CGEN

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $2.18M fell 4.7% year over year, behind the +163.4% change in trailing-twelve-month revenue. Sequentially, it fell 96.8% from the prior quarter. Over 3 fiscal years it compounded at +113.3% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $11.37M (-84.4%) for the fiscal year ending Dec 2026, a slowdown from the +161.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.18M-96.8% QoQ
Last fiscal yearDec 2025
$72.76M+161.1% YoY
LTMMar 2026
$72.66M+163.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.7%+2.2%+6.9 pp
1 year+161.1%-84.4%-245.5 pp
3-year CAGR+113.3%-24.9%-138.2 pp
5-year CAGR-13.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
72.76M USD
Year-over-year change
+161.1%
4-year CAGR
+86.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +163.4% is the 2nd highest of 6, against a peer median of -10.7%.
  • Over three fiscal years its annual growth of +113.3% compares with a peer median of -32.4%.
CGEN Competitors
Revenue for CGEN and competitors
Company Period LTM YoY 3-year CAGR
CGENCompugen Ltd.LTM Mar 2026$72.66M USD+163.4%+113.3%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$17.56M USD+74.8%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.17M USD+164.1%—
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-63.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.78M USD—-32.4%
CRDFCardiff Oncology, Inc.LTM Mar 2026$525K USD-10.7%+15.4%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD——
MOLNMolecular Partners AGLTM Mar 2026CHF 0 CHF-100.0%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD——
Peer median (excluding CGEN) —-10.7%-32.4%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$1.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.